{
  "docId": "019de076-b0fc-7764-be49-9cb0f9de8ba9",
  "docSlug": "ed8052d583ef5c8745075e02dbad124b",
  "documentTitle": "MAIA Biotechnology | Investor Presentation Deck | 31 slides",
  "authorId": "maia-biotechnology",
  "authorName": "MAIA Biotechnology",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 31,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "why_now",
  "function": "argue_timing",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "The slide uses a specific medical study to justify a change in clinical trial endpoint strategy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b0fc-7764-be49-9cb0f9de8ba9/14",
  "deckHref": "/decks/019de076-b0fc-7764-be49-9cb0f9de8ba9",
  "deckJsonHref": "/decks/019de076-b0fc-7764-be49-9cb0f9de8ba9.json",
  "deckAnchorHref": "/decks/019de076-b0fc-7764-be49-9cb0f9de8ba9#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.95,
        "x": 0.02,
        "y": 0.75
      },
      "kind": "callout",
      "text": "Since data on ORR and DCR are available simultaneously, we recommend using DCR instead of ORR as the primary endpoint in a randomized phase II trial evaluating second- or later-line chemotherapy for NSCLC.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59b1ade7-2fa7-4ef8-884d-c2d18475b56a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.42,
        "x": 0.55,
        "y": 0.22
      },
      "kind": "image",
      "text": "NIH National Library of Medicine / Translational Lung Cancer Research citation block",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ffc27ed-e7dc-4307-be4d-968e210fd822",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.48,
        "x": 0.02,
        "y": 0.18
      },
      "kind": "list",
      "text": "Disease control rate (DCR) has been demonstrated to be a better predictor of overall survival (OS) advantage compared to overall response rates (ORR) in NSCLC post first line of therapy. Meta-analysis aimed to evaluate the association of trial-level ORR and DCR with OS in randomized phase II NSCLC trials. 74 trials sourced from PubMed, Cochrane database, Embase, and Web of Science as of May 15, 2020. The correlation between trial-level odds ratio of objective response rate and hazard ratio of overall survival was weak (r=-0.29, 95% CI: -0.49 to -0.05, P=0.014), while odds ratio of disease control survival had moderate rank correlations with hazard ratio of overall survival (r=-0.53, 95% CI: -0.68 to -0.32, P<0.001).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "51aeb749-4703-4c74-b41e-758e07f24aa4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Matsumoto H et al. Transl Lung Cancer Res. 2021 May; 10(5): 2278–2289",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56bd6d55-4c36-44aa-af1a-8d4a40f4e42d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "DISEASE CONTROL RATE AS PRIMARY ENDPOINT IN NSCLC-2+ TRIALS",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6031fb6-02a9-4f55-9d56-15423fc12cba",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "authority-citation",
      "slug": null,
      "matchId": "47375467-ba92-4c7d-9224-4ec832f0826c",
      "evidence": "Citing a meta-analysis from the National Library of Medicine to support a clinical recommendation.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}